[{"id":"0a617e4d-d65e-4f5c-a559-adf45a31c05c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01738139","created_at":"2021-01-18T07:36:17.833Z","updated_at":"2024-07-02T16:35:13.511Z","phase":"Phase 1","brief_title":"Ipilimumab and Imatinib Mesylate in Advanced Cancer","source_id_and_acronym":"NCT01738139","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation • KIT positive","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • imatinib"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 02/19/2013","start_date":" 02/19/2013","primary_txt":" Primary completion: 12/13/2022","primary_completion_date":" 12/13/2022","study_txt":" Completion: 12/13/2023","study_completion_date":" 12/13/2023","last_update_posted":"2024-03-21"},{"id":"7ad2d769-2235-480c-af61-d1fa70b9f998","acronym":"","url":"https://clinicaltrials.gov/study/NCT00255346","created_at":"2021-01-18T00:51:58.980Z","updated_at":"2025-02-25T14:23:55.411Z","phase":"Phase 2","brief_title":"Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)","source_id_and_acronym":"NCT00255346","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KIT","pipe":" | ","alterations":" KIT positive","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 11/15/2005","start_date":" 11/15/2005","primary_txt":" Primary completion: 03/03/2017","primary_completion_date":" 03/03/2017","study_txt":" Completion: 03/03/2017","study_completion_date":" 03/03/2017","last_update_posted":"2023-12-18"},{"id":"b23fd882-ff28-4564-bc15-fe532fcc31ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT00700882","created_at":"2021-01-17T17:21:43.588Z","updated_at":"2024-07-02T16:35:44.187Z","phase":"Phase 2","brief_title":"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery","source_id_and_acronym":"NCT00700882","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation • KIT positive • KIT amplification","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT positive • KIT amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 07/02/2009","start_date":" 07/02/2009","primary_txt":" Primary completion: 05/06/2016","primary_completion_date":" 05/06/2016","study_txt":" Completion: 12/28/2020","study_completion_date":" 12/28/2020","last_update_posted":"2023-06-30"},{"id":"65aa546b-6373-4d3e-bd0b-ba34a643210e","acronym":"ZJGIST-01","url":"https://clinicaltrials.gov/study/NCT04933669","created_at":"2021-06-22T15:52:32.553Z","updated_at":"2024-07-02T16:36:23.163Z","phase":"Phase 2","brief_title":"Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors","source_id_and_acronym":"NCT04933669 - ZJGIST-01","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 09/07/2021","start_date":" 09/07/2021","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2021-10-12"},{"id":"8aebf424-8909-4895-a7e6-e2f46f58b8f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02642016","created_at":"2021-01-18T12:51:11.933Z","updated_at":"2024-07-02T16:36:58.921Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT02642016","lead_sponsor":"Celldex Therapeutics","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT positive • PDGFRA D842V • KIT expression","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT positive • PDGFRA D842V • KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-0158"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 01/30/2018","primary_completion_date":" 01/30/2018","study_txt":" Completion: 06/04/2019","study_completion_date":" 06/04/2019","last_update_posted":"2019-06-12"},{"id":"57c81b9c-1589-48e6-af8a-b8850f1fe404","acronym":"","url":"https://clinicaltrials.gov/study/NCT03923400","created_at":"2021-01-18T19:18:05.505Z","updated_at":"2024-07-02T16:37:00.373Z","phase":"","brief_title":"Jejunoileal vs Gastric GIST in the Era of Imatinib.","source_id_and_acronym":"NCT03923400","lead_sponsor":"Hospital Universitario Virgen de la Arrixaca","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation • KIT positive • PDGFRA mutation • KIT expression","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT positive • PDGFRA mutation • KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 77","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 01/31/2017","primary_completion_date":" 01/31/2017","study_txt":" Completion: 01/31/2017","study_completion_date":" 01/31/2017","last_update_posted":"2019-04-22"},{"id":"568fe4da-26d9-45ae-8a21-cbe099a178d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00045669","created_at":"2021-01-18T00:04:07.635Z","updated_at":"2024-07-02T16:37:02.736Z","phase":"Phase 2","brief_title":"Imatinib Mesylate in Treating Patients With Salivary Gland Cancer","source_id_and_acronym":"NCT00045669","lead_sponsor":"University Health Network, Toronto","biomarkers":" KIT","pipe":" | ","alterations":" KIT positive","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 07/01/2002","start_date":" 07/01/2002","primary_txt":" Primary completion: 01/01/2004","primary_completion_date":" 01/01/2004","study_txt":" Completion: 01/01/2005","study_completion_date":" 01/01/2005","last_update_posted":"2019-02-15"},{"id":"4029ed04-35cd-41be-abf9-1ebbe134e85b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00103168","created_at":"2021-01-18T00:19:57.940Z","updated_at":"2024-07-02T16:37:09.141Z","phase":"Phase 3","brief_title":"Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor","source_id_and_acronym":"NCT00103168","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" KIT","pipe":" | ","alterations":" KIT positive","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 908","initiation":"Initiation: 12/01/2004","start_date":" 12/01/2004","primary_txt":" Primary completion: 10/01/2008","primary_completion_date":" 10/01/2008","study_txt":" Completion: 09/01/2017","study_completion_date":" 09/01/2017","last_update_posted":"2018-07-09"},{"id":"025ca360-2cf4-403e-9a64-782a5fc251ea","acronym":"PAGIST","url":"https://clinicaltrials.gov/study/NCT01524848","created_at":"2021-01-18T06:25:31.909Z","updated_at":"2025-02-25T13:17:28.808Z","phase":"Phase 2","brief_title":"Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib","source_id_and_acronym":"NCT01524848 - PAGIST","lead_sponsor":"Scandinavian Sarcoma Group","biomarkers":" KIT • ANO1","pipe":" | ","alterations":" KIT mutation • KIT positive","tags":["KIT • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 01/01/2015","primary_completion_date":" 01/01/2015","study_txt":" Completion: 11/01/2016","study_completion_date":" 11/01/2016","last_update_posted":"2017-05-10"}]